Phaseline

Targets › FCAR

FCAR (Immunoglobulin alpha Fc receptor): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 2; Neurology, Genitourinary; next expected readout Aug 2028.

Binds to the Fc region of immunoglobulins alpha. Mediates several functions including cytokine production. (UniProt, P24071)

Open in Phaseline: the race on FCAR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Immunovant SciencesImeroprubart
FcγRIIB-FcαRI fusion protein; neonatal Fc receptor (FcRn) inhibitor
FCARPhase 2Chronic Inflammatory Demyelinating PolyneuropathyAug 2028
argenxARGX-121
IgA immune complex inhibitor; blocks FcαRI signaling pathway
FCARPhase 2Immunoglobulin A Nephropathy (IgAN)Oct 2029

Conditions

Chronic Inflammatory Demyelinating Polyneuropathy (1) Immunoglobulin A Nephropathy (IgAN) (1)

Modalities

antibody (1), protein or peptide (1)

Companies

Immunovant Sciences (1) argenx (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.